Ecron Acunova (EA), a CRO with presence in Europe and Asia, announced a joint venture with Jamjuree Innovations Co. Ltd., (JJI) Thailand. JJI is a 100% subsidiary of Chulalongkorn University Intellectual Property Foundation and enjoys strong ties with the University’s Faculty of Medicine, including Clinical Research Center (Chula CRC). The joint venture CRO is based in Bangkok and will conduct clinical research in key South East Asian countries under the name Ecron Acunova Company Ltd (EACL). Dr. Eugene Kroon MD is appointed CEO of EACL.
EA brings over two decades of clinical research experience in Ph I-IV trials, PK/PD services, clinical trial laboratory, and clinical data management on a global scale. EA has centers in oncology at Berlin, in diagnostic imaging agents in Frankfurt, and in stem cell therapy and diabetes at Bangalore. Chula CRC brings experience in PK/PD, clinical trial laboratory, data management, and HIV research in Thailand and SEA region.
Speaking on the joint venture, Dr. Kiat Ruxrungtham, Professor of Medicine, Chulalongkorn University and Chairman of EACL said, “We look forward to further expanding our model of hands-on local study and investigator relationship management in Southeast Asia for our clients through the joint venture with EA.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.